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Abstract
Background: We describe the application of an ELISA-based assay (the Peptidomatrix) that can
be used to simultaneously identify and quantitate a number of proteins in biological samples. The
biological sample (blood component, biopsy, culture or other) is first lysed to release all the
proteins, without any additional separation. The denatured proteins in the sample are then digested
in bulk with the desired proteolytic enzyme(s). The peptides in the digest are then assayed by
appropriate antibodies, using a competition ELISA protocol.
Results: As an example of its use, the present paper applies the Peptidomatrix to the assay of four
membrane proteins MDR1 (P-glycoprotein or ABCB1), MRP1 (ABCC1), BCRP/MXR (ABCG2) and
the alpha subunit of the Na, K_ATPase (ATP1A1), present in a number of cell lines and in human
lymphocytes. We show that we can detect and quantitate these proteins, using a series of peptide-
antibody pairs, and that we can differentiate between cell lines or cell preparations that express the
target proteins and those that do not.
Conclusion:  We have devised a simple, ELISA-based proteomics assay that enables the
quantitation of designated proteins in a cell or tissue sample, and that can be used in any laboratory,
with minimal specialized equipment.
Background
The revolution in biology initiated by the Genome Project
is being further stimulated by research aimed at the eluci-
dation of the proteome, the complement of proteins
expressed by an organism [1]. Proteomics aims to develop
methods for providing a total accounting of the proteins
present in a biological sample, with all the valuable
insights that will flow from achieving this aim [2-7] Much
proteomics research employs techniques such as 2D gel
electrophoresis for the separation of the protein mixtures
followed by the use of HPLC and mass spectroscopy tech-
nology for the identification of the target proteins [7,4].
However, there is a definite need for simpler and less
costly methods that can identify a limited number of pro-
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teins in a biological sample, as needed in small clinical or
research laboratories.
In this paper we describe an ELISA-based assay, the Pepti-
domatrix, based on a procedure which has been devel-
oped to identify and quantitate proteins in biopsies and
other biological samples[8,9]. Since the principle of the
assay is the use of peptides derived from a tryptic digest of
the sample, it can be used on samples that have under-
gone denaturation. Thus, an advantage of the Peptidoma-
trix is that the procedure does not require that the target
protein be present in its native form. In addition, no prior
isolation and purification of the protein target is required
for setting up the assay. All that is needed is knowledge of
the sequence of the protein (or of the mRNA that codes
for it).
The biological sample (blood fraction, biopsy, culture or
other) is first lysed to release all the proteins, without any
additional separation. The denatured proteins in the sam-
ple are then digested in bulk with the desired proteolytic
enzyme(s). The peptides in the digest are then assayed by
appropriate antibodies, using a competition ELISA proto-
col.
The Peptidomatrix assay is based on competition between
a peptide derived from a proteolytic digest of the sample
and an identical synthetic peptide, which has been pre-
bound to the ELISA plate, for an appropriate anti-
body[10].
Results
The Peptidomatrix assay uses peptides that are chosen as
being (i) specific for a target protein and (ii) present
amongst the products of tryptic digestion of that protein.
We subjected the membrane protein transporters MDR1
(or ABCB1 i.e. P-glycoprotein 1), MXR (or BCRP i.e.
ABCG2) and MRP1 (ABCC1) the alpha chain of Na, K-
ATPase (ATP1A1) to a virtual tryptic digestion and from
the products of digestion, we selected the peptides of
length 7 to 15 amino-acids. Each one of these peptides
was analyzed using the BLAST program (see methods). A
desirable peptide contains only matches that are 5 amino
acids or shorter, and a minimal number of them. The pep-
tides chosen are listed in Table 1.
The positions of these peptides in the primary sequence of
each of the four proteins are shown in Fig 1. Polyclonal
antibodies were generated in rabbits for all of these pep-
tides except in the case of the peptide denoted as P494 for
which a commercial monoclonal antibody (C494) was
available.
The Peptidomatrix assay, as described in the Introduction,
is a competition assay (Figure 2): Peptides are bound to
plastic wells. Antibodies specific to the peptide are then
added in solution and allowed to bind to the attached
peptide in the presence or the absence of a sample digest.
A calibration curve is generated in parallel with known
quantities of free synthetic peptide. The concentration of
soluble peptide in the sample is then measured by inter-
polation.
Table 1: The peptides and antibodies used throughout this study. Note that all these peptides have a cysteine at their N terminus, 
which has been added for conjugating them to a carrier protein for the immunization.
Peptide name Sequences Location Serum from rabbit
MDR1 P1 CQDVSWFDDPK 799–808 #64840, #64841
MDR1 P3 CSEIDALEMSSNDSR 646–659 #65158, #64541
MDR1 P494 MPNTLEGNVTK 1027–1036 C494 (Commercial monoclonal antibody)
MXR P1 CVGTQFIR 178–184 #65158, #64541
MXR P2 CLAEIYVNSSFYK 332–343 #64795, #64850
MXR P3 CEISYTTSFCHQLR 366–378 #64795, #64850
MXR P4 CLFIHYISGYYR 454–465 #64853, #64851
MXR P5 CNDSTGIQNR 418–426 #64853, #64851
MRP1 P1 CPSDLLQQR 1511–1518 #A0151, #A0152
MRP1 P2 CDLWSLNK 240–246 #A0151, #A0152
NaK ATPase P1 CIPFNSTNK 478–485 #64845, #64846
NaK ATPase P2 CPTTPEWVK 74–81 #64845, #64846
NaK ATPase P3 CTGTLTQNR 368–375 #64855, #64856
NaK ATPase P4 CYEPAAVSE 11–07 #64855, #64856Proteome Science 2006, 4:14 http://www.proteomesci.com/content/4/1/14
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Figure 3 shows a typical experiment in which peptide
P494 (from MDR1) and monoclonal antibody C494 were
used to detect and quantify the peptide in CEM cells, in
digests prepared from either wild-type cells (WT) or from
multidrug resistant cells (Col1000). In panel A the cali-
bration curve depicting the ELISA signal as function of free
synthetic peptide is shown as a solid line. This curve is a
descending hyperbola, since the more free peptide is
added the lower the signal. In parallel, aliquots of the cell
digest were assayed in the same way. Also in this case, the
more peptide present in the digest, the lower the signal
will be. In Figure 3A the signals from digests of WT and
Col1000 CEM cells are shown (solid and empty trian-
gles). The concentration of peptide in the digest is calcu-
lated by interpolation on the calibration curve. A simple
calculation (see Materials and Methods) yields an esti-
mate of the concentration of peptide (in ng/ml) present in
the digest. Panel B of Fig 3 summarizes the results of sev-
eral experiments such as those shown in panel A. In each
experiment, we added increasing amounts of the tryptic
digest of the wild type or drug resistant CEM cells, esti-
mated the amounts of peptide in the sample and plotted
these against the amount of added digest. The amount of
peptide detected in the drug resistant cells increases with
increasing amounts of digest while the level in the wild
type CEM cells remains close to zero.
Fig 4 depicts the means and standard errors of 15 experi-
ments performed as in Fig 3, with the data now presented
as ng of peptide detected per millions of cells. There is a
very clear difference between the data set for the drug
resistant Col1000 cells and the parent CEM cells. The plot
for the Col1000 cells is not linear, presumably because the
wells hold only a limited amount of the bound peptide.
Fitting these data to a hyperbola (i.e. Michaelis-Menten
equation) gave an estimate of the initial slope of 19.7 ±
2.5 ng peptide per million cells and a half-saturation value
of 5.2 ± 1.7 million cells. With a molecular weight of
1158.31 for the peptide, this slope translates to 10.2 mil-
lion P-glycoprotein molecules per Col1000 cell.
Interestingly, titration curves such as Fig 3A enable
another estimate to be made of the number of P-glycopro-
tein molecules per Col1000 cell. The average of the half-
Structure of the proteins detected by the Peptidomatrix Figure 1
Structure of the proteins detected by the Peptidomatrix. The ATP binding site for the ABC transporters and the loca-
tion of the peptides selected for the Peptidomatrix are indicated.
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saturation values for the 15 calibration curves performed
to generate Fig 4 was 0.678 ± 0.0678 (SE, n = 15) µg/ml
peptide. Since each well receives 100 µl of peptide solu-
tion, there is 68 ± 6.8 ng peptide in the average well at
which the antibody is one-half saturated. In Fig 4, half-sat-
uration is reached at the peptide present in 5.2 ± 1.7 mil-
lion cells. Equating these two values, one can conclude
that there are 68/5.2 or 13.0 ± 4.4 ng peptide per million
cells (or 6.7 million P-glycoprotein molecules per
Col1000 cell). This and the estimate of 19.7 ± 2.5 ng per
well found from the initial slope of the plot of Fig 4 are
less than 1 SE unit apart.
We chose to apply the Peptidomatrix protocol to the Na,
K-ATPase in order to provide a "calibrating protein" that
would be present in every animal cell type and would ena-
ble the Peptidomatrix user to normalize data in terms of
this protein. It is also a fitting control in this case since this
protein share a large similarity in structure and cellular
location with the other target proteins. Fig 5 depicts such
an experiment in which, on the same ELISA plate, samples
of a digest of leukemia cells (from patient ME) were
assayed for MDR1 using the P3 peptide and the appropri-
ate polyclonal antibody and, in parallel, were assayed for
the Na, K-ATPase using the P4 peptide and appropriate
polyclonal antibody. Parts A and B of this figure show the
peptide concentration obtained (with the procedure of Fig
3) with these two proteins separately, while Fig 5C shows
the level of MDR1 P3 plotted against that of Na/K-ATPase
P4. The regression through the points has a slope of 0.65,
indicating that on a mole-for-mole basis, these cells mem-
branes contain three molecules of the sodium pump for
every two MDR1 molecules.
Fig 6 shows a summary compilation of data from this and
five other experiments where this internal calibration pro-
tocol was applied to white blood cell samples taken from
five different patients. In all these experiments, duplicate
samples of cells from four or five patients were assayed on
the same ELISA plate for both proteins. The ratio of P-glyc-
oprotein polypeptide to the Na, K-ATPase polypeptide
was computed for each patient sample and this ratio nor-
malized to that of a particular reference sample (the cells
from patient VR, mean ratio of PgP P3/ATPase P4 = 0.714
± 0.237) for displaying in Fig 6. The amount of MDR1 is
significantly higher (at p < 0.05) in the sample from
patient SR than in those from patients VR and SH, and the
normal donor, but not in that from ME. In one experi-
ment of the series, a sample of the Col1000 drug-resistant
cells was included on the ELISA plate. The ratio of MDR1
P3 peptide to ATPase P4 peptide in this sample was 13
times higher than that for the reference VR cells depicted
in Fig 6. These cells, just like other cell lines, seem to have
a very low level of Na, K-ATPase, which may not be a good
normalizing control in this case.
To test the validity of the Peptidomatrix protocol we com-
pared the results obtained with an independent method
of testing for MDR levels: a clinically established func-
tional method based on the uptake of the dye Rhodamine
123 (rho123), used on clinical samples. In cells that
express functional PgP, rho123 is rapidly and actively
pumped out of the cell and, within a short period of time,
marked differences in intracellular fluorescence are seen
between cells that have or have not extruded rho123 via
this ATP-dependent pump[11]. PgP-reversing drugs, like
Verapamil, can be used in the rho123 retention assay to
preferentially block PgP function[12].
The clinical samples were either fresh samples or frozen
samples of white blood cells. All the lymphocyte prepara-
tions were from peripheral blood or from leukopheresis
treatment. The frozen samples had been kept at -70°C for
up to six years and the Rhodamine uptake assay had been
performed and recorded at the time of the collection.
Multidrug sensitive CEM cells (wt) and resistant CEM cells
(col) served as controls. Because counting cells in the fro-
zen samples was not possible, the parameter for the
The procedure of the 'Peptidomatrix' assay Figure 2
The procedure of the 'Peptidomatrix' assay. The 
ELISA Peptidomatrix is a competition assay: Peptides are 
bound to the plastic wells and they are subsequently exposed 
to antibodies generated against them. A labeled secondary 
antibody is used to detect the bound primary antibodies. In 
the assay itself the antibodies are mixed with soluble syn-
thetic peptide in known amounts, to generate a calibration 
curve. The peptide in solution competes with the bound pep-
tide and will affect the signal. As shown schematically in the 
figure: Panel A, A': No free peptide is added, thus the signal 
will be the highest. Panel B, B': A small amount of free pep-
tide is added and the signal will be intermediate. Panel C, C': 
A large amount of competing peptide is added, thus no anti-
body binds to the well and the signal is minimal.
A’ C’ B’
A C B
A’ A’ C’ C’ B’ B’
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number of cells that was used was the concentration of
protein. The protein concentration was measured using
the Bradford method before the lysis of the cells and pre-
cipitation of the protein. The MDR protein levels in the
samples were determined by the Peptidomatrix using the
MDR P3 peptide and are expressed as ng peptide per mg
protein.
Table 2 shows a comparison of the results obtained from
the Peptidomatrix with those from the functional analy-
sis. Care was taken to ensure that the dates of the samples
that had been tested by the functional assay and the fro-
zen samples tested by the Peptidomatrix assay were
matched, because of the known variation of the expres-
sion of the protein in the same patient at different times.
The results in Table 2 are summarized in qualitative terms
(negative, low positive, positive and high positive) and
their correlation was tested by using Pearson's correlation.
The Pearson's correlation between the Peptidomatrix
assay and the rhodamine uptake assay was calculated as
0.79.
In order to validate the quantification of PgP by another
method that is independent of the Peptidomatrix assay,
PgP was also quantified by the ATPase activity assay and
the results obtained by the two methods were compared.
The determination of the number of PgP molecules based
on ATPase activity was performed on purified membranes
obtained from CEM- col cells, using the ATPase activity
associated with PgP, using both the basal activity and the
verapamil (10 µM)-stimulated activity. In one typical
experiment the basal ATPase activity was 23.2 mM Pi/µg
protein/hour and the verapamil-stimulated activity was
82.7 mM Pi/µg protein/hour. As detailed in the Methods
section the final volume of the liberated Pi determination
was 260 µl. These data were converted to number of mol-
ecules/mg protein using the following turnover numbers:
2.9 s-1 for the basal activity and 9.9 s-1 for the verapamil-
stimulated activity respectively[13]. The final calculated
values were 3.48 × 1014 molecules PgP/mg protein and
3.63 × 1014 molecules/mg protein for the stimulated and
the basal activity. The data were obtained from quadrupli-
cate samples. To measure the PgP amount by Peptidoma-
trix an inhibition curve with synthetic peptide (PgP P3)
was run alongside an analogous curve run with dilution of
a tryptic digest of the same purified membranes used
above. The Kd's (half saturation points) of the two curves
were 2.87 × 10-2 µg/ml peptide and 3.11 µl digest respec-
tively. Given that the concentration of the digest (deter-
mined prior to digestion) is 25 mg/ml, the molecular
weight of the peptide is 1111 daltons, and the volume of
the ELISA reaction is 100 µl, the amount of PgP in the
membranes comes to 3.03 × 1014 molecules PgP/mg pro-
tein, a value very close to the one obtained from the
ATPase assay. In a series of experiments using different
preparations of membranes, the values for the number of
Detection of the MDR1 peptide P494 Figure 3
Detection of the MDR1 peptide P494. In panel A calibration curves are plotted as optical density (OD450) vs. peptide 
concentration. The curve is the calculated regression fit, based on the hyperbolic equation detailed in the Materials and Meth-
ods section. The OD values of 50 µl of cell digest (approximately 4.5 million cells) from wild type and drug-resistant CEM cells 
are shown as solid and empty triangles respectively. For the sake of clarity we have added arrows to indicate the position of 
these points on the curve. In panels B the amounts of peptide (in nanograms) for a range of digest volumes (from 6.25 µl to 50 
µl) are shown. These values have been calculated using the regression curve of panels A.
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molecules of Pgp per mg membrane protein obtained by
the two methods were 5.49 ± 1.14 × 1014 (standard error
n = 4) and 5.46 ± 1.73* 1014 (standard error n = 4) for the
ATPase (combining the data from basal and verapamil
stimulated) and Peptidomatrix respectively.
In fig 7 Peptidomatrix data are shown for two additional
membrane proteins, MRP1, studied in a drug sensitive cell
line (VP16) and the parent MCF7 cell line (Fig 7A and 7B)
and MXR, studied in drug-sensitive (AdVp) and wild type
MCF7 cell lines (Fig 7C). The Peptidomatrix assay shows
that the parental strain is low in MRP while the drug-
resistant line is rich in this protein (Fig 7B).
From the initial slope of the line drawn through the empty
circles, it can be calculated that there are some 1.69 ± 0.38
million molecules of the MRP1 protein per single MCF-7
Vp 16 cell. The wild-type cell line had little if any of the
MRP1 protein, by this assay.
Discussion
The recent advances in proteomics research have fostered
the emergence of many different techniques for identify-
ing and quantitating proteins from cells and tissues. In
order to apply these scientific advances to the world of
routine clinical diagnostics there is a need for a simple
and easy-to-use method. We present here a possible
answer to this need in the form of the Peptidomatrix, and
describe, as an example, its use for identifying, and assay-
ing quantitatively, four membrane proteins present in
digests of wild type and multidrug-resistant cell lines and
in white blood cells of leukemia patients. The assay is
ELISA-based and uses antibodies directed against small
peptides that have been selected as being (i) likely to be
liberated by tryptic digestion of cells and (ii) unique to the
particular protein under investigation. We found that
many of the peptides that we synthesized on the basis of
these criteria, as being suitable for use in the Peptidoma-
trix protocol, did give us useful peptide-antibody combi-
nations. Most of the peptides that were designed for use
with the proteins P-glycoprotein, MRP1, and MXR gave
satisfactory differences in signal when wild type and drug
resistant cell strains were compared (Figs 3–4 and 6–7),
suggesting that they were identifying a protein that was
present in the drug resistant cells but not in the parental
strains. Such a test could not be made for the peptide/anti-
body pairs made against the ubiquitous Na, K-ATPase.
The protein for which we have most substantial data is
MDR1 (also known as P-glycoprotein or ABCB1) that con-
fers multi-drug resistance to cells in culture and is associ-
ated with drug resistance in cancer patients. For this
protein, the peptide P494, the epitope of the monoclonal
antibody C494, allows the specific identification of the
protein in cell digests from a drug-resistant line of human
T-lymphoblastic leukemia cells, the Col1000 cells. Fig 3
exemplifies the competition assay that we use in the Pep-
tidomatrix protocol. The data from individual experi-
ments can be transformed into plots of peptide vs.
number of cells. Fig 4 summarized the results of 15 exper-
iments using the Peptidomatrix protocol on these cells.
Fitting the data by a linear hyperbola enables the initial
slope of the curve to be determined. This initial slope is in
units of nanograms of peptide present per million cells.
Since the molecular weight of the peptide is known, the
data can be translated into a number that is equivalent to
the amount of P-glycoprotein molecules per cell. The
number that we calculated is 10.2 million P-glycoprotein
molecules per Col1000 cell. We wished to compare these
values with other similar quantifications reported in the
literature.
Although there have been very many studies of the expres-
sion of the MDR1 mRNA levels and of the protein in drug
resistant cells, the latter using western blots or FACS anal-
ysis, we have been able to find only two quantitative stud-
ies that record the amount of P-glycoprotein present in
such cells. One study[14] used the FACS technique and an
antibody depletion method on three lines of mouse 3T3
cells. The highly resistant line (N3-2400) was found to
have 14.2 × 106 molecules of PgP/cell[15], a value quite
close to the one that we detected in the highly resistant
CEM cell. The other quantitative study of P-glycoprotein
Average (± SE) of 15 experiments detecting P494 in CEM  cells Figure 4
Average (± SE) of 15 experiments detecting P494 in 
CEM cells. The abscissa values have been recalculated in 
millions of cells, in order to deduce the number of PgP mole-
cules per cell (see text for details).
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molecules per cell is by Maynadie and colleagues[16].
These authors also used a FACS technique, but calibrated
the FACS signal with a set of beads labeled with a fluores-
cent dye[17]. They measured P-glycoprotein in a sensitive
and drug resistant erythroleukemic cell line (the K562 and
K562-ADR cells). These cells had 291 and 303,481 P-glyc-
oprotein molecules per cell, respectively. It must be
pointed out that the K562-ADR cells are indeed resistant
to doxorubicin, but much less so than the CEM cells that
we used in this study and the 3T3 line mentioned previ-
ously).)[18]. Maynadie and colleagues also reported data
on human leukemic cells and found very variable num-
bers for their P-glycoprotein content, ranging from 117 to
10,947 (mean 2509 ± 2805) molecules per cell, in the
cells from the 25 donors studied[16]. Our results seem to
confirm the large individual variability in the amount of
PgP in white blood cells. Comparison between the Pepti-
domatrix method and a clinically established functional
method, Rhodamine 123 uptake, shows a high correla-
tion (Pearson's correlation of 0.79) between the two
methods (Table 2). Peptidomatrix testing of MDR 1 pro-
tein in AML patients showed that 66% of them express the
protein. This fits roughly with estimates in the literature,
which show that 35–80 % of AML patients express the
protein. This provides support for the reliability of Pepti-
domatrix as a diagnostic tool for identifying the presence
or absence of the P-gp protein in patients.
The results obtained with Peptidomatrix were compared
with several other accepted biochemical methods. West-
Simultaneous detection of Na/K ATPase and MDR1 proteins in cells from a leukemia patient Figure 5
Simultaneous detection of Na/K ATPase and MDR1 proteins in cells from a leukemia patient. In Panel A and B 
the measured amounts of the peptides PgP P3 and ATPase P4 (in ng/well) are plotted as function of the amounts of cells. In 
panel C the same calculated amounts of peptides are plotted one against the other, allowing the calculation of the ATPase to 
PgP ratio over a range of cell amounts.
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ern blotting and RT-PCR, which provide only qualitative
results, were fully consistent with the Peptidomatrix
results (data not shown). We determined the number of
P-glycoprotein molecules per cell, by measuring the
ATPase activity of this protein and combining this with
the known turnover number of the enzyme. This provided
a quantitative result, enabling direct comparison with the
Peptidomatrix. The specificity of the ATPase method for P-
gp was ensured by including in the assay mixture inhibi-
tors of all the irrelevant ATPases. The two procedures, Pep-
tidomatrix and ATPase activity were in excellent accord.
Thus, as far as can be assessed, the Peptidomatrix protocol
provides a reliable method for identifying and quantitat-
ing the MDR 1 that was used in the present study.
An important point to discuss here is the general applica-
bility of the Peptidomatrix and its ability to detect low-
abundance proteins. In this study we worked with 4 differ-
ent proteins, which, although similar in structure and cel-
lular location have different sequences and distributions.
The Peptidomatrix procedure, run with the appropriate
peptide-antibody pair is clearly able to detect all of them.
In experiments (not shown) in which we mismatched
protein, peptide and antibody, we generally obtained
background values and we could not build a calibration
curve, indicating that the specificity of the system, at least
for the range of proteins that we examined, is quite good.
Virtually all the peptides chosen, listed in Table 1, were
active and specific when tested, a fact that clearly indicates
the broad applicability of the method. As for the sensitiv-
ity of the method we must say that there is room for
improvement. The PgP experiments shown in Figure 3
and 4 indicate an LOD in the submicromolar range (10-7–
10-8 M). This is a very high value, which may not always
be adequate, although in the context of the PgP field it
may be. However, a look at the data in Figure 7B shows
that the LOD for MRP using the MRP I peptide and cog-
nate antibody is in the range of 10-14 M, which clearly
indicates that there is the potential for an adequately sen-
sitive assay.
The proteins we studied were chosen merely on the
grounds of this laboratory's familiarity with them. We
offer the Peptidomatrix procedure, however, as a general
solution to the problem of finding a simple and easily set
up method for such assays in many biological research
and clinical situations. All it requires is selecting suitable
peptides in the proteins to be assayed and preparing anti-
bodies against them. Once these are available, reliable
estimates of the amounts of the specified protein can be
made from digests of a variety of biological material.
Conclusion
We have devised a simple, ELISA-based proteomics assay
that enables the quantitation of designated proteins in a
cell or tissue sample, and that can be used in any labora-
tory, with minimal specialized equipment.
Methods
Peptide selection
The peptides on which the ELISA is based are chosen using
a three-fold screening process: First, a list is made of all the
peptides that are likely to be present in a tryptic digest of
the protein to be identified. This can be done using a sim-
ple word processing program or more specialized soft-
ware. Next, peptides are selected that have lengths of
between 7 and 15 amino acids. Each peptide from this
selection is checked for its uniqueness amongst all the
polypeptide chains that comprise the human proteome,
using the BLAST program (parameters: PAM 30 Gap Costs
Existence 5, Extension 2). The main criterion for this stage
of selection is the presence of matches to other known
proteins that are 5 amino acids or shorter. From this lim-
ited list, we chose the more hydrophilic peptides as being
those that would be most likely to be good antigens
[20,21] A number of these selected peptides were ulti-
mately chosen for production of antibodies, and then
used in the protocol described below
The peptides chosen for this investigation are shown in
Table 1.
Antibodies
The polyclonal antibodies used throughout this study
were generated in rabbits by Affinity Bioreagents, Inc.
Ratio of MDR1 P3 to Na/K ATPase P4 in white blood cell  preparations from leukemia patients and normal controls Figure 6
Ratio of MDR1 P3 to Na/K ATPase P4 in white blood 
cell preparations from leukemia patients and normal 
controls. The average of at least 5 independent experiments 
is shown here. The amounts of the proteins were deter-
mined with the Peptidomatrix protocol and the ratios calcu-
lated in each experiment. In order to combine the 
experiments the data were normalized for one of the sam-
ples (VR, taken as reference).
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(ABR, Golden, CO). The antigen for immunization was
also prepared by ABR, including the synthesis of the pep-
tides, the conjugation to a carrier and the injection to rab-
bits. The rabbits were bled once before immunization and
3 or 4 times after immunization. The titers were recorded
and the various bleedings kept and used for the develop-
ment of the immunoassay.
Monoclonal antibody C494 was purchased from Dako
(Glostrup, Denmark)
Cells
CEM (WT; Col1000.) These cells are described in Kohler
and Stein [19].
CEM cell lines were grown in suspension in a 5% CO2
atmosphere at 37°C using RPMI-1640 medium (Biologi-
cal Industries, Kibbutz Beit Ha'emek, Israel) supple-
mented with 10 % fetal calf serum, 2 mM glutamate, 100
U ml-1 penicillin, 100 µg ml-1 streptomycin, 250 µg ml-1
amphotericin. The human lymphoblastoid cell line CEM
Col1000 was derived from the line CEM ADR5000 by
growing the original cells over four weeks in medium with
1000 ng ml-1 colchicine. They were maintained in this
concentration of colchicine.
MCF7 cells are human breast cancer cells. The two drug-
resistant lines, VP-16, and AV, were generated by trans-
forming them with plasmids expressing MRP1 and MXR
respectively. The cells were grown in DMEM medium sup-
plemented with fetal calf serum and antibiotics as
described above. The growth medium of the VP-16 line
was supplemented with 4 µM etoposide while the AV line
was grown in the presence of 5 µg/ml verapamil and 3 µg/
ml adriamycin.
Peripheral blood lymphocytes
Peripheral blood mononuclear cells were separated over
Ficoll gradients. Ficoll separation was performed in most
cases on the same day, and when this was not possible,
whole blood was kept at 4°C and separated the following
day. Cells were suspended in RPM1 1640 with 10% fetal
calf serum until analysis, generally on the same day or up
to 48 h later.
Sample preparation
Pellets of 20 million CEM or white blood cells (or 5 mil-
lion MCF7 cells) were dissolved by re-suspending the
sample in 250 µl 2% SDS in PBS and incubated at room
temperature for 10 minutes. The protein was precipitated
by adding 4 volumes of methanol/acetic acid pH 4.0 (15
Table 2: Summary of presence of P-glycoprotein in patient samples, as detected with the Peptidomatrix and the Rhodamine uptake 
assay.
Patient Type of leukemia Peptidomatrix results (ng peptide/mg protein) Peptidomatrix results (Grade) Status by FACS (Grade)
CEM wt 7 Negative
CEM col1000 114 Positive
1 AP AML 72.5 Positive (low) Positive
2 DA T-ALL 26.37 Positive (low) Negative
3 GB t-AML 150 Positive (high) Positive
4 KA T-ALL 0 Negative Negative
5 RE AML 144 Positive (high) Positive
6 WE AML 12.2 Positive (low) Positive (low)
7 SA AML 7 Negative Negative
8 SN AML 90.93 Positive (low) Positive
9 SY CLL 209 Positive (high) Positive
10 WR APL 4.9 Negative Negative
11 YN AML 7.9 Negative Negative
12 CM AML 6 Negative Negative
13 DM CML 62.27 Positive (low) Positive
14 GG AML 4.8 Negative Negative
15 SG AML 56.4 Positive (low) Positive
16 OZ AML 38.5 Positive (low) Positive (low)
The table compares the results that we have from the clinical functional method, Rhodamine 123 uptake and the Peptidomatrix assay (see text). 
The Rhodamine 123 uptake assay is based on the differential dye retention in the absence and presence of Verapamil, an inhibitor of Pgp. The 
MDR1 protein levels in the samples were determined by the Peptidomatrix using the MDR P3 peptide and are expressed as ng peptide per mg 
protein. Multidrug sensitive CEM cells (wt) and resistant CEM cells (col1000) served as controls. To allow a comparison with the semiquantitative 
data of the other assay a gradation of MDR1 levels was defined by comparison to the control cells: The samples that had levels similar to the wt 
cells ± 10 % (up to 8 ng/mg protein) were graded as negative, the samples that had levels similar to the col1000 cells (100–125 ng/mg) were graded 
as positive, the samples that had levels higher (> 125 ng/mg) or lower then the col1000 cells (8–100 ng/mg) were graded as high-positive or low-
positive respectively. The data shown are averages of duplicates, the difference between the duplicates were below 5%.Proteome Science 2006, 4:14 http://www.proteomesci.com/content/4/1/14
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ml methanol/40 µl glacial acetic acid) and incubating
overnight at -20°C. The protein was then pelleted by cen-
trifugation at 13,000 rpm, in an Eppendorf centrifuge
(16,000 g) for 20 min at 4°C. The pellets were washed
twice with ethanol and air-dried before re-suspension.
Protein digestion
To the protein pellet were added 70 µl of a solution con-
taining 0.03 M Tris HCl, 2 mM CaCl2, and 10 µg/ml
DNAase I. After incubation for 10 minutes at 37°C, 130
µl of a solution containing 2 M urea, 0.05% SDS and
0.02% NaN3 were added. After incubation for 10 addi-
tional minutes at 37°C, 20 µl of a stock solution of TPCK-
treated Trypsin (SIGMA) (40 mg/ml) was added and the
reaction mix was incubated for 20 hr at 37°C. The trypsi-
nolysis was stopped by boiling the digest for 10 minutes.
In parallel, a stock of digestion buffer, containing all the
components but no protein samples, was prepared, to be
used as diluent in the assay.
ELISA
Maxisorp ELISA plates (NUNC, Denmark) were coated
overnight at 4°C, with 100 µl of a0.1–2 µg/ml solution of
the relevant synthetic peptide in 0.1 M carbonate buffer
pH 9.6 and blocked 2 hours at room temperature with
200 µl blocking buffer (3% BSA/0.05% Tween 20 in phos-
phate buffered saline, PBS: 0.01 M phosphate buffer, 150
mM NaCl, pH 7.2). Serial binary dilutions of the synthetic
Detection of the proteins MRP 1 and MXR Figure 7
Detection of the proteins MRP 1 and MXR. Panel A and B show an experiment detecting the protein MRP1 in wild type 
and transformed MCF7 cells, using the MRP P1 peptide and one of the specific antisera. Again a calibration curve and a calcu-
lated peptide amount vs. cell amount are shown. In panel C an experiment detecting the MXR protein in wild type and trans-
formed MCF7 cells is shown. Similarly to Figure 3A we have marked the readings of wt and resistant cell digests with a solid 
and an empty triangle respectively.
AProteome Science 2006, 4:14 http://www.proteomesci.com/content/4/1/14
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peptide (from 5 to 0.078 µg/ml) and a blank sample were
prepared in 50% digestion buffer containing 1 × PBS, 3%
BSA, 0.05% Tween 20 and the desired immune serum
diluted 1:3000. When monoclonal antibody C494 was
used it was diluted to 0.1 µg/ml. These solutions were
used for the calibration curve. The experimental samples
contained 50 % cell digest, antibody as above and no
additional peptide. 100 µl of these solutions were added
to the wells and incubated at room temperature 1–3
hours. The wells were washed 4 times with 1 × PBS/0.05%
Tween 20 and then 100 µl of horseradish peroxi-
dase(HRP)-conjugated secondary Ab (anti-mouse or anti-
rabbit) diluted 1:10,000 or 1:20,000 in blocking buffer
were added in each well. After incubation for one hour at
room temperature and washing, as above, the bound HRP
conjugate was detected by adding 100 µl of tetramethyl
benzidine. The peroxidase reaction was stopped after 5
minutes by the addition of 50 µl 0.5 M H2SO4. Optical
densities at 450 nm were measured using an ELISA reader.
Data determination
The data from the Elisa plate reader are fed into a data
analysis template in the program Sigmaplot (SPSS, Chi-
cago, IL). A plot of the OD450 vs. the concentration of the
antibody or the concentration of the free peptide is drawn.
The plot is then fitted, using a regression program, to a
hyperbola fitting an ascending (Equation. 1) or a descend-
ing (Equation. 2) hyperbolic 3-parameter equation, as
described in the text:
where Amax is the calculated maximal amplitude of the
curve, D the predicted minimum of the ELISA readings,
corresponding essentially to the background signal, S the
concentration of the antibody or the attached peptide (in
equation 1) or the free peptide (in equation 2) and Kd is
the concentration that gives one-half of the shift between
maximum and minimum readings.
Rhodamine uptake
Peripheral blood mononuclear cells, prepared as
described above, were stained with rhodamine-123 using
the method outlined by Chaudhary and Roninson [22].
We used 150 ng/ml of rhodamine-123 for staining, for 15
min at 37°C with an efflux time of 2 h; 10 mM verapamil
was used as an MDR1 inhibitor. Cells were counterstained
with propidium iodide immediately prior to analysis to
identify dead cells (if any were present), which were
removed from the analysis by gating. We defined a posi-
tive result as one in which the Kolmogorov-Smirnov
(abbreviated K-S) D value [23] was equal to or greater
than 0.15 [24-26].
Plasma membranes preparation
The cells were harvested in a table top centrifuge at 1000
rpm × 5 min, and washed twice with 20 mM Hepes pH =
7.4/0.9% NaCl buffer. The cells were then resuspended in
lysis buffer (10 mM Hepes-Tris pH = 7.4, 2 mM DTT, 5
mM EDTA, 5 mM EGTA) containing protease inhibitors
(cocktail from Sigma) at a concentration of 30 millions/
ml. The cells were incubated in ice for 15 minutes and all
subsequent procedures were performed at 4°C. The cells
were homogenized in a Teflon-glass homogenizer (40
strokes), until 70% disruption. The lysis of the cells was
examined under the light microscope. The homogenate is
centrifuged for 10 minutes at 3000 rpm (300 g) in a tab-
letop centrifuge to spin down nuclei and unlysed cells.
Subsequently the mitochondria were removed by centrif-
ugation at 5500 rpm (4000 g) in a Sorvall centrifuge
(rotor SS34) for an additional 10 minutes. The superna-
tant was then transferred to an ultracentrifuge tube and
centrifuged at 35,000 rpm (114,000 g) in a 70 Ti rotor for
45 min. In this third and final centrifugation the plasma
membranes were sedimented. The supernatant was dis-
carded, the membrane pellet was resuspended in 500–
1000 µl of lysis buffer and homogenized by aspiration 5
times through a 22 gauge syringe. The isolated mem-
branes were stored at -70°C in aliquots.
ATPase assay
The PgP-associated ATPase was determined colorimetri-
cally as the vanadate-sensitive release of inorganic phos-
phate from ATP hydrolysis (REF). 1 µg membrane protein
were incubated in ATPase buffer (50 mM KCl, 2.5 mM
MgSO4, 0.5 mM EGTA, 3 mM DTT, 3 mM ATP, 2 mM
oubain, 3 mM sodium azide, 25 mM Tris/HCl pH 7.4)
and verapamil (10 µM), if desired. The reaction was car-
ried out in 96 well microtiter plates in a final volume of
60 µl in the presence or the absence of 0.25 mM sodium
orthovanadate. The microtiter plate was incubated at
37°C for one hour and the reaction was terminated by
adding 200 µl of stop solution (0.2% ammonium molyb-
date, 1.3% sulfuric acid, 0.9% SDS and 1% ascorbic acid).
After an additional 30 minutes of incubation the absorb-
ance at 620 nm was read in a microplate reader. ATPase
activity was expressed in mmol Pi/hr/mg protein.
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